Oxis International Inc. Announces Request for Euronext Trading Suspension

TAMPA, Fla., March 31, 2015 /PRNewswire/ -- Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company focused on biotech cancer therapy development and commercialization, announced today Oxis CEO Tony Cataldo has requested a suspension of the trading of Oxis common shares on the Euronext exchange. Oxis shares will continue to trade on the OTCQB under the symbol OXIS.  

Oxis Chairman and CEO Tony Cataldo stated, "As Oxis continues to move forward with its strategies launched in 2014 and 2015, we must constantly evaluate all components of our business and our markets. We are taking this time to consider the value to our shareholders of Oxis shares trading in multiple markets. Our plans for OXIS shareholders trading abilities this year, incorporates our desire to up list to a NASDAQ National Market listing as we continue to bring in high value biotech assets to Oxis Biotech, Inc. Management will make a decision on the resumption of trading on the Euronext after the evaluation period has ended. We want all shareholders to know the suspension is an Oxis corporate decision. Oxis is fully current and approved for trading on the OTCQB and the Euronext exchange. All shareholders can be assured normal trading continues on the OTCQB under the symbol OXIS without interruption."

Shareholders and interested parties are invited to participate in our previously announced conference call where the trading suspension will be explained in more detail.  The call will start promptly at 4:15pm EST on Tuesday, March 31, 2015. The dial in number for the call is 712.775.7031. Meeting ID number is 576-591-822.

Contact

Jonathan Barkman
Riverview Capital Enterprises
1275 Glenlivet Dr Ste 100
Allentown, PA 18106
office 866-845-0105
fax 484-224-2999

ABOUT OXIS BIOTECH, INC. - OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the worlds leading cannabinoid researchers and institutions to advance it's technologies.

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Oxis International, Inc.